Oryzon Genomics S.A.
A clinical-stage biopharma developing epigenetic therapies for cancer and CNS disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Manufacturing
Description
Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-27 18:57 |
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
|
Spanish | 437.0 KB | ||
| 2025-02-27 00:00 | Spanish | 13.7 MB | |||
| 2025-01-25 17:32 |
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 202.6 KB | ||
| 2025-01-25 12:28 |
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 55.5 KB | ||
| 2025-01-25 00:00 |
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 55.5 KB | ||
| 2024-11-21 17:53 |
Solicitud de conversión de bonos T3-1
|
Spanish | 89.4 KB | ||
| 2024-10-24 18:02 |
La sociedad remite información sobre los resultados del tercer trimestre de 2024
|
Spanish | 388.3 KB | ||
| 2024-10-01 07:47 |
Oryzon recibe el acta de la reunión de Fin-de-Fase II con la FDA para vafidemst…
|
Spanish | 318.9 KB | ||
| 2024-09-24 13:37 |
Solicitud de conversión de bonos T2-5 y T3-1
|
Spanish | 87.2 KB | ||
| 2024-09-23 08:10 |
ORYZON presenta los datos finales de su ensayo de Fase IIb PORTICO de vafidemst…
|
Spanish | 338.8 KB | ||
| 2024-08-13 13:03 |
Ampliación de capital por conversión de bonos convertibles (T2-5)
|
Spanish | 88.4 KB | ||
| 2024-07-19 20:16 |
Ampliación de capital por conversión de bonos convertibles (T2-4)
|
Spanish | 73.7 KB | ||
| 2024-07-03 15:58 |
Ampliación de capital por conversión de bonos convertibles (T2-3)
|
Spanish | 89.6 KB | ||
| 2024-06-28 14:48 |
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de …
|
Spanish | 279.2 KB | ||
| 2024-06-26 14:22 |
Ampliacion de capital por conversion de Bonos
|
Spanish | 84.8 KB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
